Background: It is unknown if discontinuation of targeted therapy (TT) and readministration in case of recurrence is feasible in patients with metastatic renal cell carcinoma (mRCC) in which complete response (CR) is achieved by TT alone or no evidence of disease (NED) with additional resection of residual metastases.
introduction
Metastatic renal cell carcinoma (mRCC) carries a poor prognosis, with a median survival duration in the range of 1-year and a 2-year survival rate of only 10%-20% [1] . Approximately one-third of patients present with metastatic disease at the time of their initial diagnosis and a further 25% will develop metastases at a later stage. For several years, antiangiogenic targeted therapies (TT) have become available and changed the treatment paradigm for patients with mRCC [1] . Understanding of the underlying molecular biology of renal cell carcinoma (RCC) has established the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways as relevant therapeutic targets. The small molecule multitargeted tyrosine kinase inhibitors sunitinib and sorafenib, the combination of the monoclonal anti-VEGF antibody bevacizumab and interferon and the mTOR inhibitors temsirolimus and everolimus have recently been approved and recommended for first-and second-line treatment of mRCC [2] [3] [4] [5] [6] [7] [8] [9] . With these agents, complete responses (CRs) are rare events, but objective responses [partial response (PRs)] can be achieved in 10%-39% of patients.
Given the emerging role of TT, multimodal approaches to mRCC have been re-examined. In the era of cytokine-based therapy, consolidation of a PR or prolonged stabilization by surgical resection of residual disease was a beneficial option for a small proportion of patients with mRCC [10] . With the new antiangiogenic agents, CRs are still rare, but PRs do occur much more frequently compared with cytokines. These patients might benefit from additional surgical resection of residual metastases, thereby possibly achieving a longer disease control [11] . In view of the fact that TT of mRCC in general remains a palliative, long-term continuous treatment, toxicity, impairment of quality of life and also the high cost of these therapies are becoming increasingly important issues. Thus, an intriguing question is whether these agents can be safely discontinued in highly selected patients with mRCC who achieve a CR and resumed in case of recurrence of measurable disease. We have recently reported the first outcome results of such an approach from a retrospective analysis including 12 patients [12] . Here, we report on the outcome of discontinuation of TT in 36 patients with mRCC and a CR after TT alone or no evidence of disease (NED) following TT and complete residual metastasectomy, including those from our previous report.
patients and methods patients
Medical records of patients treated with TT for mRCC in the different institutions from November 2005 to March 2010 were reviewed. Inclusion criteria for this analysis were (i) absence of previously present measurable disease in imaging studies according to the RECIST, achieved either by tumor nephrectomy and TT or by tumor nephrectomy, TT and additional metastasectomy and (ii) subsequent discontinuation of TT. Patients were classified according to the Memorial Sloan-Kettering Cancer Center (MSKCC) risk criteria (based on the five risk factors: low Karnofsky performance status < 80, high lactate dehydrogenase > 1.5 times the upper limit of normal, low serum hemoglobin, high corrected serum calcium > 10 mg/dl and time from initial diagnosis to TT of <1 year [13] ). Some of the patients had been included in expanded access protocols (sunitinib and sorafenib). In the expanded access programs, each participant signed an institutional review board-approved protocol-specific informed consent in accordance with national and institutional guidelines. Adverse events were assessed according to the National Cancer Institute-Common Toxicity Criteria (version 3.0). Sunitinib was administered orally at a dose of 50 mg daily, consisting of 4 weeks on treatment followed by a 2-week rest period in cycles of 6 weeks. Sorafenib was administered orally at a dose of 800 mg daily as a continuous regimen. Two patients received a dose escalation of sorafenib to 1600 mg daily. Bevacizumab was administered i.v. at a dose of 10 mg/kg every 2 weeks, while interferon was given at a starting dose of 9 MIU s.c. three times weekly. Temsirolimus was administered i.v. at a dose of 25 mg once weekly.
methods
Outcome criteria analyzed after discontinuation of TT were time off TT, recurrence of previously existing metastases (defined as relapse) versus occurrence of new metastatic sites (defined as disease progression) and response to re-exposure to TT. In addition, the improvement or disappearance of treatment-related adverse events as well as symptoms caused by tumor progression were evaluated. Tumor assessment was based on imaging with computed tomography (CT) or magnetic resonance imaging scans according to the RECIST criteria by one-dimensional measurement of the sum of diameters of all target lesions. Tumor response was assessed every two to three cycles of treatment. Descriptive statistics were calculated for the patients' characteristics. Associations between main characteristics and response to treatment or toxicity were explored using the chi-square test. Progression-free survival and overall survival were estimated using the Kaplan-Meier method. Furthermore, variables potentially predictive of outcome following discontinuation of TT were analyzed using explorative univariate and multivariate Cox proportional hazards models. P values <0.05 were considered statistically significant.
results
Patient characteristics are summarized in Table 1 . All patients had histologically proven RCC, with clear cell subtype in 34 cases, including one with a minor component of sarcomatoid differentiation, one had a sarcomatoid tumor and another patient had papillary RCC. Median patient age was 65 years (range 32-78), 25 were male (69.4%) and 11 female (30.6%). MSKCC good and intermediate risk criteria were present in 14 (38.9%) and 22 (61.1 %) patients, respectively. None of the patients had poor-risk criteria. Eighteen patients (50%) had no previous systemic treatments, 15 (41.7%) had one and 3 (8.3%) had two previous treatments before the one that led to CR/ NED. Median time since nephrectomy was 4 years (range 1-13) and median number of metastatic sites was 2 (range 1-5). In 16 cases (44.4%), CR was achieved with TT alone and 20 patients (55.6%) were rendered NED after additional metastasectomy ( Table 2 ). Median time until NED or CR occurred was 12 months (range 3-26). The antiangiogenic agents that led to NED or CR were sunitinib in 22 cases (61.1%), sorafenib in 11 (30.6%), bevacizumab and interferon in 2 cases (5.5%) and temsirolimus in 1 (2.8%).
Previous treatments and best responses are depicted in Table  1 . Time on TT before discontinuation and severe toxic effects are provided in Table 2 . Grade 3/4 toxic effects were present in 19 patients (52.8%), 14 patients (38.9%) needed dose reductions. However, all patients had grades 1 and 2 sideeffects, some of them significantly bothersome, in particular fatigue and hand-foot syndrome. Eight patients reduced sunitinib and five patients reduced sorafenib dosing due to toxicity. In one patient, interferon was reduced to 4.5 MIU. No dose reductions were necessary for bevacizumab and temsirolimus.
Outcome after discontinuation of TT is shown in Table 2 . At a median follow-up after discontinuation of TT of 12 months (range 3-31), a disease recurrence was observed in 24 patients (66.7%), in 10 cases with new metastatic sites (progression). Symptomatic progression occurred in three cases with bone metastases. In two of these, onset of symptoms preceded the scheduled CT restaging. Twelve patients (33.3%) remained recurrence free from RCC (with a secondary malignancy necessitating radiochemotherapy in one case). Median time off TT in all patients was 7 months (range 1-31). All patients had less or no toxic effects and reported better quality of life during the time period off TT, as apparent from the medical records.
In an exploratory analysis, potential predictive variables were tested in Cox models. None of the explored variables including time since first diagnosis, MSKCC risk group, objective response to prior therapy, number of previous therapies, number of metastatic sites, CR to TT alone or NED following additional metastatectomy and the antiangiogenic agent that led to CR/NED were associated with time to recurrence/ progression after discontinuation of TT neither in univariate nor in multivariable-adjusted models (Table 3) .
TT was readministered in 23 cases (63.9%), with the same drug in 18 cases and a switch to another agent in 5 cases. Additional local therapies (surgery and radiotherapy) were applied in five5 patients, delaying the necessity of readministration of TT for a variable time in three of these. Response to re-exposure to TT was CR in 1 (4.3%), PR in 8 (34.8%, including 1 near CR), stable disease (SD) in 11 (47.8%) and progressive disease (PD) in 3 patients (13.0%). Only one patient received no further treatment upon disease progression (sunitinib-related severe heart failure).
conclusions
In contrast to previously available cytokine-based therapies for mRCC, antiangiogenic treatment with targeted agents is characterized by manageable toxicity and a higher clinical benefit (objective responses + disease stabilizations) in up to 80% of patients [1, 14] . On the other hand, continuous longterm TT is required to maintain a response, whereas some patients treated with cytokines may remain stable for long periods of time without additional treatment. While antiangiogenic drugs may be effective within weeks after initiation of treatment, rapid regrowth of tumors and metastases may occur following their discontinuation. Evidence for this rebound phenomenon has been reported and attributed to early regrowth of tumor vascularization or to tumoral edema [15, 16] . These data may suggest that it would be unsafe to discontinue TT in patients who benefit from this treatment. However, the differential mechanisms of angiogenesis inhibition on primary tumors and metastases and the influence of treatment duration may be much more complex than previously thought: a withdrawal phenomenon of spontaneous regression in mRCC progressive to sunitinib, observed following discontinuation of this drug, has recently been reported [17] . Preclinical data show that the effects evoked by angiogenesis inhibitors on primary tumors and their metastases differ and may actually be divergent [18, 19] . These findings are as yet unexplained.
A series of reports suggest that substantial objective responses may be achieved in a subset of patients with TT and that complete residual metastasectomy may be beneficial in selected patients who experience a PR with antiangiogenic treatment [11, 20, 21] . The question whether TT may be discontinued in these patients with CR or NED following TT with or without additional metastasectomy has not been addressed in these reports.
The first available data regarding the outcome of such an approach has been reported by our group in a multicenter retrospective analysis including 12 patients treated with sunitinib and sorafenib (6 CRs and 6 PRs followed by complete residual metastasectomy) [12] . At a short median follow-up of 8.5 months since discontinuation of TT, 7 of 12 patients remained without recurrence and 5 patients had recurrent disease. Median time off TT was 7.5 months (range 3-25). Readministration of TT was effective in all cases. More recently, a similar report has been published regarding successful treatment of five patients with TT, in whom there was no remaining measurable disease left (two CRs under treatment with sorafenib and three PRs with sorafenib and sunitinib followed by residual metastasectomy) [22] . Three of these patients subsequently discontinued treatment and remain free of disease for 29, 16 and 11 months, respectively.
In our current study, which includes all 12 patients from the previous publication [12] , median time off TT in all patients was 7 months, but some patients remained without TT for as long as 31 months. Since in five patients recurrence following discontinuation of TT was managed with local treatments (radiation or metastasectomy), they were not restarted on TT immediately, only at the time of recurrence that required systemic treatment. Consequently, given the importance of local interventions for all these selected patients, time off TT and not time to recurrence was evaluated in our study. In contrast to the previous report, however, the majority of patients (66.7%) experienced a disease recurrence or progression. An interesting finding of the current analysis is that in this situation, readministration of TT yielded an objective response in 9 of 23 cases (39.1%), and in further 11 cases (47.8%), SD was achieved. We were unable to find an association between potentially predictive clinical variables and outcome after discontinuation of TT neither in univariate nor in multivariableadjusted models. However, due to the limited sample size, power for such analyses is too limited to finally conclude on the relevance of these variables in this clinical scenario.
Our current study has a number of important limitations. Firstly, the small number of patients and the retrospective design incur the probability of bias. No central radiologist review of all CT scans was carried out. The benefit in quality of life without systemic treatment, although obvious from clinical records, could not be substantiated because no reliable assessments using appropriate questionnaires were implemented. A cost analysis has also not been carried out. There were no uniform criteria for the timing of discontinuation of TT after NED was achieved. The line of treatment at which CR or NED are achieved, e.g. first-line versus second-or third-line therapy, may have an influence on the outcome after discontinuation of TT. However, due to the inability to predict the response of different targeted agents in individual patients and the rarity of CRs or near CRs that would allow to render these patients disease free hamper a prospective evaluation of such an approach. It must be emphasized that the type of patients included in this study, although generally increasing due to the availability of numerous new treatments for mRCC, is highly selected and does not reflect the general patient population with mRCC.
In conclusion, outcome after discontinuation of TT in selected cases with mRCC and CR or NED is variable. Factors that may correlate with successful outcome of such an approach could not be identified in this retrospective study. Re-exposure to TT in case of recurrence was effective in almost all patients, suggesting that sensitivity to the same agent is retained in this situation. Thus, discontinuation of TT in cases with mRCC and NED cannot be recommended in general but may be a feasible strategy in selected and appropriately informed patients. The lack of treatment-related side-effects must be weighed against the risk of disease progression.
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